2026 Interim Report
Filed with HKEX · Stock code 1011 · · 37 pages · English
2 CORPORATE INFORMATION 3 MANAGEMENT DISCUSSION AND ANALYSIS 8 CORPORATE GOVERNANCE AND OTHER INFORMATION 14 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS 15 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENT OF OTHER COMPREHENSIVE INCOME 16 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION 17 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANG
China NT Pharma Group Co., Ltd. on 6ix
Earlier from China NT Pharma
- Voluntary announcement in relation to the application for compulsory enforcement by a wholly-owned subsidiary in respect of the shareholders' right to information of beijing kangchen biological technology co., limited
- Inside information announcement arbitration award
- Appointment of auditor
- Connected transaction in relation to loan capitalisation involving subscription of shares under Specific mandate
- Supplemental announcement retirement of auditor
Later from China NT Pharma
- Notification Letter and Reply Form to Registered Shareholder
- Notification Letter and Request Form to Non-Registered Holder
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Appointment of auditor and notice of extraordinary general meeting
- Notice of extraordinary general meeting
Follow China NT Pharma into a list and get an email when it puts out news.
Follow China NT Pharma